Preserved value of bone scintigraphy for the detection of skeletal metastases in prostate cancer patients with low prostate-specific antigen levels: Effect of hormonal therapy and poor histologic differentiation

Clinical Nuclear Medicine

Volumn 27, Issue 7, 2002, Pages 532-533

  Caglar, Meltem ^a   Tuncel, Murat ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Bone Scintigraphy; Hormonal Therapy; Prostate Cancer; Prostate Specific Antigen

Indexed keywords

FLUTAMIDE; MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN;

AGED; ANTIGEN DETECTION; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CASE REPORT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; DRUG EFFECT; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; MALE; PROSTATE CANCER;

AGED; BONE NEOPLASMS; HUMANS; LEG BONES; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SPINE; TECHNETIUM TC 99M MEDRONATE; WHOLE-BODY COUNTING;

EID: 0036660891     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-200207000-00017     Document Type: Article

References (7)

1. Crawford ED: Hormonal therapy of prostatic carcinoma. Cancer 66:1035, 1990.
2. Leo ME, Bilhartz DL, Bergstralh EJ, et al: Prostate specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status? J Urol 145:802, 1991.
3. Bruchovsky N, Brown EM, Coppin CM, et al: The endocrinology and treatment of prostate tumor progression. Prog Clin Biol Res 142:773, 1984.
4. Chybowski FM, Keller JJL, Bergstralh EJ, et al: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters. J Urol 145:313, 1991.
5. Vijayakumar V, Vijayakumar S, Quadri SF, et al: Can prostate specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer? Am J Clin Oncol 17:432, 1994.
6. Rudoni M, Antonini G, Favro M, et al: The clinical value of prostate specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med 22:297, 1995.
7. Younes E, Haas GP, Montie JE, et al: Value of preoperative PSA in predicting pathologic stage of patients undergoing salvage prostatectomy. Urology 43:22, 1994.